The Drug-Induced Respiratory Disease Website
Or 'ILD'. (Fr: PnP subaiguë). A.k.a. pulmonary infiltrates. Generally bilateral and symmetrical. Gradual onset. Consistent with but not specific for an NSIP-c pattern on pathology. Less- dense, severe, acute and diffuse than pattern Ia. Lacks the features of ARDS that may accompany pattern Ia. Can be in the form of disseminated linear, reticulonodular, miliary or patchy opacities. BAL is indicated to separate this pattern from PIE (Ic) or DAH (IIIa). Acute chest pain can be at the forefront. A search for microorganisms including Pneumocystis (stains, PCR) is indicated. On pathology (although not many cases undergo a confirmatory lung biopsy), there is interstitial inflammation and a more or less dense cellular interstitial cellular infiltrate (NSIP-c). Fibrosis, alveolar edema and/or a reactive epithelium denote those cases resulting from with antineoplastic chemotherapy agents. The frontier between patterns Ia and I b can be difficult to draw, so please check drugs under both Ia and Ib. Patients may quickly shift from pattern Ib to Ia particularly if the the causal drug is inappropriately continued. Prompt withdrawal must be considered, underlying disease permitting, and can be therapeutic.
Publications
Imatinib-related interstitial lung disease.
British journal of haematology 2018 03;180;780 — 2018 03 — 780
Acute pulmonary complications in patients with hematologic malignancies.
Radiographics : a review publication of the Radiological Society of North America, Inc 2014 Oct;34;1755-68 — 2014 Oct — 1755-68
Interstitial pneumonitis in a patient with chronic myeloid leukemia.
Turkish journal of haematology : official journal of Turkish Society of Haematology 2013 Dec;30;435-6 — 2013 Dec — 435-6
Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.
International journal of hematology 2013 Feb;97;299-300 — 2013 Feb — 299-300
Nakashima S, Kakugawa T, Motomura H, Hirano K, Sasaki E, Nagata Y, Kinoshita A, Sakamoto N, Ishimatsu Y, Mukae H, Kohno S
Development of imatinibmesylate-induced interstitial lung disease 2?weeks after discontinuation of the treatment: a case report.
Multidisciplinary respiratory medicine 2012 Nov 23;7;48 — 2012 Nov 23 — 48
Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
Leukemia & lymphoma 2012 Feb;53;332-3 — 2012 Feb — 332-3
[A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Terapevticheskii arkhiv 2010;82;59-61 — 2010 — 59-61
[Imatinib-induced pulmonary toxicity].
Gaceta medica de Mexico 2009 Sep-Oct;145;437-9 — 2009 Sep-Oct — 437-9
Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.
Leukemia 2006 Jun;20;1162-4 — 2006 Jun — 1162-4
Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.
Respiration; international review of thoracic diseases 2008;75;350-4 — 2008 — 350-4
Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
American journal of hematology 2005 May;79;80-1 — 2005 May — 80-1
Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms.
Internal medicine journal 2005 Feb;35;136-7 — 2005 Feb — 136-7
Imatinib mesylate-induced interstitial pneumonitis.
Mayo Clinic proceedings 2003 Dec;78;1578-9 — 2003 Dec — 1578-9
Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Aug 15;21;3171-3 — 2003 Aug 15 — 3171-3
Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, Socié G, Calvo F, Gluckman E, Ribaud P, Rousselot P, Tazi A
Hypersensitivity pneumonitis related to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Oct 15;20;4271-2 — 2002 Oct 15 — 4271-2